Sankar Kamya, Nagrath Sunitha, Ramnath Nithya
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-5848, USA.
Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109-5848, USA.
Cancers (Basel). 2021 Mar 23;13(6):1476. doi: 10.3390/cancers13061476.
Rearrangements in the Anaplastic Lymphoma Kinase () gene have been implicated in 5-6% of all non-small cell lung cancers. -rearranged non-small cell lung cancers are sensitive to -directed tyrosine kinase inhibitors, but generally resistant to single-agent immune checkpoint inhibitors. Here, we aim to describe the mechanisms of aberrations in non-small cell lung cancer by which an immunosuppressed tumor microenvironment is created, leading to host immune evasion. We report pre-clinical and clinical studies evaluating novel immunotherapeutic approaches and describe the promises and challenges of incorporating immune-based treatments for -rearranged non-small cell lung cancer.
间变性淋巴瘤激酶（ALK）基因重排在所有非小细胞肺癌中占5%-6%。ALK重排的非小细胞肺癌对ALK靶向酪氨酸激酶抑制剂敏感，但通常对单药免疫检查点抑制剂耐药。在此，我们旨在描述非小细胞肺癌中ALK畸变导致免疫抑制性肿瘤微环境形成并进而导致宿主免疫逃逸的机制。我们报告了评估新型免疫治疗方法的临床前和临床研究，并描述了将基于免疫的治疗方法应用于ALK重排非小细胞肺癌的前景和挑战。
Zotero 插件